30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Sionna Therapeutics Inc (SION)

Track

Over the last 90 days, Sionna Therapeutics Inc. has seen significant insider selling activity, totaling over $132 million. Notably, OrbiMed Private Investments VIII, LP and OrbiMed Advisors LLC, along with Peter A. Thompson, have been involved in numerous planned and proposed sales. No insider purchases were recorded during this period.
Stock chart
Ticker: SION Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
OrbiMed Private Investments VIII, LP
Shareholder
2 sales — total 55,359,854 USD
Proposed sale 29 May 2026
Value US$3,721,397.41 | Price 155.91 | Shares 92,661
Proposed sale 29 May 2026
Value US$3,797,231.72 | Price 346.03 | Shares 68,021
Planned sale 27 May 2026
Value US$2,712,994.69 | Price 340.58 | Shares 88,560
Planned sale 27 May 2026
Value US$4,493.49 | Price 44.49 | Shares 101
Planned sale 11 May 2026
Value US$8,534,014.58 | Price 46.22 | Shares 184,639
Planned sale 11 May 2026
Value US$8,534,014.58 | Price 46.22 | Shares 184,639
Planned sale 8 May 2026
Value US$2,664,412.86 | Price 44.58 | Shares 59,767
Planned sale 8 May 2026
Value US$2,664,412.86 | Price 44.58 | Shares 59,767
Planned sale 7 May 2026
Value US$2,165,637.06 | Price 44.61 | Shares 48,546
Planned sale 7 May 2026
Value US$2,165,637.06 | Price 44.61 | Shares 48,546
Planned sale 18 Apr 2026
Value US$131,244.96 | Price 44.52 | Shares 2,948
Planned sale 18 Apr 2026
Value US$131,244.96 | Price 44.52 | Shares 2,948
Planned sale 17 Apr 2026
Value US$2,341,097.96 | Price 44.68 | Shares 52,397
Planned sale 17 Apr 2026
Value US$2,341,097.96 | Price 44.68 | Shares 52,397
Planned sale 16 Apr 2026
Value US$10,287,918.04 | Price 45.34 | Shares 226,906
Planned sale 16 Apr 2026
Value US$10,287,918.04 | Price 45.34 | Shares 226,906
Planned sale 15 Apr 2026
Value US$10,528,924.32 | Price 44.64 | Shares 235,863
Planned sale 15 Apr 2026
Value US$10,528,924.32 | Price 44.64 | Shares 235,863
Planned sale 14 Apr 2026
Value US$2,128,201.14 | Price 44.51 | Shares 47,814
Planned sale 14 Apr 2026
Value US$2,128,201.14 | Price 44.51 | Shares 47,814
Planned sale 5 Mar 2026
Value US$347,018.88 | Price 33.86 | Shares 10,250
Proposed sale 5 Mar 2026
Value US$354,342.50 | Price 34.57 | Shares 10,250
Sale 3 Feb 2026
Value US$1,295,628.54 | Price 44.58 | Shares 29,063
Sale 3 Feb 2026
Value US$1,295,628.54 | Price 44.58 | Shares 29,063
Sale 3 Feb 2026
Value US$1,295,628.54 | Price 44.58 | Shares 29,063
Sale 3 Feb 2026
Value US$1,295,628.54 | Price 44.58 | Shares 29,063
Sale 2 Feb 2026
Value US$84,237.30 | Price 44.57 | Shares 1,890
Sale 2 Feb 2026
Value US$84,237.30 | Price 44.57 | Shares 1,890
Sale 22 Jan 2026
Value US$10,000,000.00 | Price 40.00 | Shares 250,000
Proposed sale 22 Jan 2026
Value US$8,173,010.59 | Price 41.77 | Shares 195,667
Proposed sale 22 Jan 2026
Value US$2,269,489.41 | Price 41.77 | Shares 54,333
Sale 24 Dec 2025
Value US$1,486,009.80 | Price 44.55 | Shares 33,356
Sale 24 Dec 2025
Value US$1,486,009.80 | Price 44.55 | Shares 33,356
Sale 19 Dec 2025
Value US$38,928.75 | Price 44.49 | Shares 875
Sale 19 Dec 2025
Value US$38,928.75 | Price 44.49 | Shares 875
Sale 18 Dec 2025
Value US$4,449.00 | Price 44.49 | Shares 100
Sale 18 Dec 2025
Value US$4,449.00 | Price 44.49 | Shares 100
Sale 17 Dec 2025
Value US$40,050.00 | Price 44.50 | Shares 900
Sale 17 Dec 2025
Value US$40,050.00 | Price 44.50 | Shares 900
Planned sale 5 Dec 2025
Value US$415,330.00 | Price 40.52 | Shares 10,250
Proposed sale 5 Dec 2025
Value US$419,020.00 | Price 40.88 | Shares 10,250
Sale 26 Nov 2025
Value US$71,184.00 | Price 44.49 | Shares 1,600
Sale 26 Nov 2025
Value US$71,184.00 | Price 44.49 | Shares 1,600
Sale 25 Nov 2025
Value US$530,294.00 | Price 44.60 | Shares 11,890
Sale 25 Nov 2025
Value US$530,294.00 | Price 44.60 | Shares 11,890
Sale 24 Nov 2025
Value US$4,212,726.82 | Price 44.54 | Shares 94,583
Sale 24 Nov 2025
Value US$4,212,726.82 | Price 44.54 | Shares 94,583
Proposed sale 24 Nov 2025
Value US$46,500,032.60 | Price 44.38 | Shares 1,047,770
Sale 21 Nov 2025
Value US$300,555.50 | Price 39.50 | Shares 7,609
Sale 21 Nov 2025
Value US$254,380.00 | Price 39.50 | Shares 6,440
Sale 21 Nov 2025
Value US$391,998.00 | Price 39.50 | Shares 9,924
Sale 21 Nov 2025
Value US$47,795.00 | Price 39.50 | Shares 1,210
Proposed sale 21 Nov 2025
Value US$281,170.40 | Price 43.66 | Shares 6,440
Proposed sale 21 Nov 2025
Value US$52,828.60 | Price 43.66 | Shares 1,210
Proposed sale 21 Nov 2025
Value US$433,281.84 | Price 43.66 | Shares 9,924
Proposed sale 21 Nov 2025
Value US$332,208.94 | Price 43.66 | Shares 7,609
Sale 20 Nov 2025
Value US$24,462.00 | Price 40.50 | Shares 604
Sale 20 Nov 2025
Value US$20,736.00 | Price 40.50 | Shares 512
Sale 20 Nov 2025
Value US$31,914.00 | Price 40.50 | Shares 788
Sale 20 Nov 2025
Value US$3,888.00 | Price 40.50 | Shares 96
Sale 20 Nov 2025
Value US$37,775.83 | Price 39.89 | Shares 947
Sale 20 Nov 2025
Value US$31,951.89 | Price 39.89 | Shares 801
Sale 20 Nov 2025
Value US$49,264.15 | Price 39.89 | Shares 1,235
Sale 20 Nov 2025
Value US$5,983.50 | Price 39.89 | Shares 150
Proposed sale 20 Nov 2025
Value US$51,128.22 | Price 38.94 | Shares 1,313
Proposed sale 20 Nov 2025
Value US$78,775.62 | Price 38.94 | Shares 2,023
Proposed sale 20 Nov 2025
Value US$9,579.24 | Price 38.94 | Shares 246
Proposed sale 20 Nov 2025
Value US$60,395.94 | Price 38.94 | Shares 1,551
Proposed sale 19 Nov 2025
Value US$466,066.00 | Price 38.41 | Shares 12,134
Proposed sale 19 Nov 2025
Value US$89,115.00 | Price 39.12 | Shares 2,278
Proposed sale 19 Nov 2025
Value US$550,568.00 | Price 38.41 | Shares 14,334
Proposed sale 19 Nov 2025
Value US$718,113.00 | Price 38.41 | Shares 18,696
Sale 19 Nov 2025
Value US$365.49 | Price 40.61 | Shares 9
Sale 19 Nov 2025
Value US$324.88 | Price 40.61 | Shares 8
Sale 19 Nov 2025
Value US$487.32 | Price 40.61 | Shares 12
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-01 2026-05-29 PrS Proposed sale
2.6
OrbiMed Private Investments VIII, LP

Shareholder
92,661
155.91
US$3,721,397 		92,661 155.91 US$3,721,397
2026-05-29 2026-05-29 PrS Proposed sale
2.6
OrbiMed Private Investments VIII, LP

Shareholder
68,021
346.03
US$3,797,232 		68,021 346.03 US$3,797,232
2026-05-29 2026-05-27 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
88,560 -33.0%
340.58
US$2,712,995 		88,560 -33.0% 340.58 US$2,712,995
2026-05-29 2026-05-27 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
101 -0.0%
44.49
US$4,493 		101 -0.0% 44.49 US$4,493
2026-05-11 2026-05-11 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
184,639 -6.5%
46.22
US$8,534,015 		184,639 -6.5% 46.22 US$8,534,015
2026-05-11 2026-05-11 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
184,639 -6.5%
46.22
US$8,534,015 		184,639 -6.5% 46.22 US$8,534,015
2026-05-11 2026-05-08 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
59,767 -2.0%
44.58
US$2,664,413 		59,767 -2.0% 44.58 US$2,664,413
2026-05-11 2026-05-08 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
59,767 -2.0%
44.58
US$2,664,413 		59,767 -2.0% 44.58 US$2,664,413
2026-05-11 2026-05-07 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
48,546 -1.6%
44.61
US$2,165,637 		48,546 -1.6% 44.61 US$2,165,637
2026-05-11 2026-05-07 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
48,546 -1.6%
44.61
US$2,165,637 		48,546 -1.6% 44.61 US$2,165,637
2026-04-21 2026-04-18 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
2,948 -0.1%
44.52
US$131,245 		2,948 -0.1% 44.52 US$131,245
2026-04-21 2026-04-18 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
2,948 -0.1%
44.52
US$131,245 		2,948 -0.1% 44.52 US$131,245
2026-04-21 2026-04-17 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
52,397 -1.7%
44.68
US$2,341,098 		52,397 -1.7% 44.68 US$2,341,098
2026-04-21 2026-04-17 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
52,397 -1.7%
44.68
US$2,341,098 		52,397 -1.7% 44.68 US$2,341,098
2026-04-16 2026-04-16 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
226,906 -7.0%
45.34
US$10,287,918 		226,906 -7.0% 45.34 US$10,287,918
2026-04-16 2026-04-16 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
226,906 -7.0%
45.34
US$10,287,918 		226,906 -7.0% 45.34 US$10,287,918
2026-04-16 2026-04-15 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
235,863 -6.8%
44.64
US$10,528,924 		235,863 -6.8% 44.64 US$10,528,924
2026-04-16 2026-04-15 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
235,863 -6.8%
44.64
US$10,528,924 		235,863 -6.8% 44.64 US$10,528,924
2026-04-16 2026-04-14 PlS Planned sale
3.0
Thompson Peter A.
Non-Executive Director
47,814 -1.4%
44.51
US$2,128,201 		47,814 -1.4% 44.51 US$2,128,201
2026-04-16 2026-04-14 PlS Planned sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
47,814 -1.4%
44.51
US$2,128,201 		47,814 -1.4% 44.51 US$2,128,201
2026-03-06 2026-03-05 PlS Planned sale
Fitzpatrick Jennifer

Chief Legal Officer

Officer
10,250 -100.0%
33.86
US$347,019 		10,250 -100.0% 33.86 US$347,019
2026-03-05 2026-03-05 PrS Proposed sale
JENNIFER FITZPATRICK

Officer

Officer
10,250
34.57
US$354,342 		10,250 34.57 US$354,342
2026-02-04 2026-02-03 S Sale
3.0
Thompson Peter A.
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-03 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-03 S Sale
3.0
Thompson Peter A.
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-03 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
29,063 -0.8%
44.58
US$1,295,629 		29,063 -0.8% 44.58 US$1,295,629
2026-02-04 2026-02-02 S Sale
3.0
Thompson Peter A.
Non-Executive Director
1,890 -0.1%
44.57
US$84,237 		1,890 -0.1% 44.57 US$84,237
2026-02-04 2026-02-02 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
1,890 -0.1%
44.57
US$84,237 		1,890 -0.1% 44.57 US$84,237
2026-01-26 2026-01-22 S Sale
3.2
TPG GP A, LLC
Large shareholder
250,000 -3.7%
40.00
US$10,000,000 		250,000 -3.7% 40.00 US$10,000,000
2026-01-22 2026-01-22 PrS Proposed sale
Rise Fund Sling, L.P.

Stockholder

Large shareholder
195,667
41.77
US$8,173,011 		195,667 41.77 US$8,173,011
2026-01-22 2026-01-22 PrS Proposed sale
Rise Fund Sling II, L.P.

Stockholder

Large shareholder
54,333
41.77
US$2,269,489 		54,333 41.77 US$2,269,489
2025-12-29 2025-12-24 S Sale
3.0
Thompson Peter A.
Non-Executive Director
33,356 -0.9%
44.55
US$1,486,010 		33,356 -0.9% 44.55 US$1,486,010
2025-12-29 2025-12-24 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
33,356 -0.9%
44.55
US$1,486,010 		33,356 -0.9% 44.55 US$1,486,010
2025-12-19 2025-12-19 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
875 -0.0%
44.49
US$38,929 		875 -0.0% 44.49 US$38,929
2025-12-19 2025-12-19 S Sale
3.0
Thompson Peter A.
Non-Executive Director
875 -0.0%
44.49
US$38,929 		875 -0.0% 44.49 US$38,929
2025-12-19 2025-12-18 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
100 -0.0%
44.49
US$4,449 		100 -0.0% 44.49 US$4,449
2025-12-19 2025-12-18 S Sale
3.0
Thompson Peter A.
Non-Executive Director
100 -0.0%
44.49
US$4,449 		100 -0.0% 44.49 US$4,449
2025-12-19 2025-12-17 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
900 -0.0%
44.50
US$40,050 		900 -0.0% 44.50 US$40,050
2025-12-19 2025-12-17 S Sale
3.0
Thompson Peter A.
Non-Executive Director
900 -0.0%
44.50
US$40,050 		900 -0.0% 44.50 US$40,050
2025-12-09 2025-12-05 PlS Planned sale
Fitzpatrick Jennifer

Chief Legal Officer

Officer
10,250 -100.0%
40.52
US$415,330 		10,250 -100.0% 40.52 US$415,330
2025-12-05 2025-12-05 PrS Proposed sale
JENNIFER R FITZPATRICK

Officer

Officer
10,250
40.88
US$419,020 		10,250 40.88 US$419,020
2025-11-26 2025-11-26 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
1,600 -0.0%
44.49
US$71,184 		1,600 -0.0% 44.49 US$71,184
2025-11-26 2025-11-26 S Sale
3.0
Thompson Peter A.
Non-Executive Director
1,600 -0.0%
44.49
US$71,184 		1,600 -0.0% 44.49 US$71,184
2025-11-26 2025-11-25 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
11,890 -0.3%
44.60
US$530,294 		11,890 -0.3% 44.60 US$530,294
2025-11-26 2025-11-25 S Sale
3.0
Thompson Peter A.
Non-Executive Director
11,890 -0.3%
44.60
US$530,294 		11,890 -0.3% 44.60 US$530,294
2025-11-26 2025-11-24 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
94,583 -2.6%
44.54
US$4,212,727 		94,583 -2.6% 44.54 US$4,212,727
2025-11-26 2025-11-24 S Sale
3.0
Thompson Peter A.
Non-Executive Director
94,583 -2.6%
44.54
US$4,212,727 		94,583 -2.6% 44.54 US$4,212,727
2025-11-24 2025-11-24 PrS Proposed sale
2.6
OrbiMed Private Investments VIII, LP

Shareholder
1,047,770
44.38
US$46,500,033 		1,047,770 44.38 US$46,500,033
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
7,609 -4.6%
39.50
US$300,556 		7,609 -4.6% 39.50 US$300,556
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
6,440 -0.3%
39.50
US$254,380 		6,440 -0.3% 39.50 US$254,380
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
9,924 -1.5%
39.50
US$391,998 		9,924 -1.5% 39.50 US$391,998
2025-11-24 2025-11-21 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,210 -0.0%
39.50
US$47,795 		1,210 -0.0% 39.50 US$47,795
2025-11-21 2025-11-21 PrS Proposed sale
RA Capital Nexus Fund III, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
6,440
43.66
US$281,170 		6,440 43.66 US$281,170
2025-11-21 2025-11-21 PrS Proposed sale
RA Capital Healthcare Fund LP

Director; 10% Stockholder

Non-Executive Director Large shareholder
1,210
43.66
US$52,829 		1,210 43.66 US$52,829
2025-11-21 2025-11-21 PrS Proposed sale
RA Capital Nexus Fund, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
9,924
43.66
US$433,282 		9,924 43.66 US$433,282
2025-11-21 2025-11-21 PrS Proposed sale
BLACKWELL PARTNERS LLC - SERIES A

Director; 10% Stockholder

Non-Executive Director Large shareholder
7,609
43.66
US$332,209 		7,609 43.66 US$332,209
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
604 -0.4%
40.50
US$24,462 		604 -0.4% 40.50 US$24,462
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
512 -0.0%
40.50
US$20,736 		512 -0.0% 40.50 US$20,736
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
788 -0.1%
40.50
US$31,914 		788 -0.1% 40.50 US$31,914
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
96 -0.0%
40.50
US$3,888 		96 -0.0% 40.50 US$3,888
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
947 -0.6%
39.89
US$37,776 		947 -0.6% 39.89 US$37,776
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
801 -0.0%
39.89
US$31,952 		801 -0.0% 39.89 US$31,952
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,235 -0.2%
39.89
US$49,264 		1,235 -0.2% 39.89 US$49,264
2025-11-24 2025-11-20 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
150 -0.0%
39.89
US$5,984 		150 -0.0% 39.89 US$5,984
2025-11-20 2025-11-20 PrS Proposed sale
RA Capital Nexus Fund III, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
1,313
38.94
US$51,128 		1,313 38.94 US$51,128
2025-11-20 2025-11-20 PrS Proposed sale
RA Capital Nexus Fund, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
2,023
38.94
US$78,776 		2,023 38.94 US$78,776
2025-11-20 2025-11-20 PrS Proposed sale
RA Capital Healthcare Fund LP

Director; 10% Stockholder

Non-Executive Director Large shareholder
246
38.94
US$9,579 		246 38.94 US$9,579
2025-11-20 2025-11-20 PrS Proposed sale
BLACKWELL PARTNERS LLC - SERIES A

Director; 10% Stockholder

Non-Executive Director Large shareholder
1,551
38.94
US$60,396 		1,551 38.94 US$60,396
2025-11-19 2025-11-19 PrS Proposed sale
RA Capital Nexus Fund III, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
12,134
38.41
US$466,066 		12,134 38.41 US$466,066
2025-11-19 2025-11-19 PrS Proposed sale
RA Capital Healthcare Fund LP

Director; 10% Stockholder

Non-Executive Director Large shareholder
2,278
39.12
US$89,115 		2,278 39.12 US$89,115
2025-11-19 2025-11-19 PrS Proposed sale
BLACKWELL PARTNERS LLC - SERIES A

Director; 10% Stockholder

Non-Executive Director Large shareholder
14,334
38.41
US$550,568 		14,334 38.41 US$550,568
2025-11-19 2025-11-19 PrS Proposed sale
RA Capital Nexus Fund, L.P.

Director; 10% Stockholder

Non-Executive Director Large shareholder
18,696
38.41
US$718,113 		18,696 38.41 US$718,113
2025-11-19 2025-11-19 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
9 -0.0%
40.61
US$365 		9 -0.0% 40.61 US$365
2025-11-19 2025-11-19 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
8 -0.0%
40.61
US$325 		8 -0.0% 40.61 US$325
2025-11-19 2025-11-19 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
12 -0.0%
40.61
US$487 		12 -0.0% 40.61 US$487
Explore more

More insider trading research around Sionna Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America